Industry / Netherlands
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
PER.C6 Technology Advances Present New Opportunities In Cell Culture Biopharmaceuticals
June 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
In a development that could significantly cut the cost of producing biopharmaceuticals, Dutch firms DSM Biologics and Crucell have announced record yield results using Crucell's human cell culture technology, PER.C6. Using the technology, DSM was able to yield 27 grams per litre, surpassing all other reported titre levels to